Maass N, Schem C, Bauerschlag DO, Tiemann K, Schaefer FW, Hanson S, Muth M, Baier M, Weigel MT, Wenners AS, Alkatout I, Bauer M, Jonat W, Mundhenke C (2014)
Publication Type: Journal article
Publication year: 2014
Book Volume: 87
Pages Range: 300-310
Journal Issue: 5
DOI: 10.1159/000365553
Background: Imatinib is a tyrosine kinase inhibitor of BCR-ABL, ABL, PDGFR-α and -β, KIT, and DDR. In solid tumors, it inhibits proliferation and invasiveness and facilitates higher intratumoral cytotoxic drug concentrations. Vinorelbine has good tolerability and efficacy in metastatic breast cancer (MBC). This study evaluates the safety and efficacy of imatinib and vinorelbine in combination.
APA:
Maass, N., Schem, C., Bauerschlag, D.O., Tiemann, K., Schaefer, F.W., Hanson, S.,... Mundhenke, C. (2014). Final safety and efficacy analysis of a phase I/II trial with imatinib and vinorelbine for patients with metastatic breast cancer. Oncology, 87(5), 300-310. https://dx.doi.org/10.1159/000365553
MLA:
Maass, Nicolai, et al. "Final safety and efficacy analysis of a phase I/II trial with imatinib and vinorelbine for patients with metastatic breast cancer." Oncology 87.5 (2014): 300-310.
BibTeX: Download